

PATENT APPLICATION
Serial No. 09/806,178
Atty. Docket No. 702-010411

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit Not Yet Assigned :
In re application of : **USE OF COMPOUNDS THAT REDUCE**
ALPHA2-ANTIPLASMIN IN VIVO FOR
Nobuo NAGAI et al. : **THE PREPARATION OF COMPOSITION**
Serial No. 09/806,178 : **FOR THE TREATMENT OF ISCHEMIC**
Filed June 18, 2001 : **STROKE**
Examiner - Not Yet Assigned :

Pittsburgh, Pennsylvania
August 29, 2001

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to the requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants submit this Information Disclosure Statement which includes a completed Form PTO -1449. The references identified in Form PTO-1449 were cited in the International Search Report for the underlying PCT Application No. PCT/EP99/07405 or in the specification. Copies of the International Search Report and references cited in the specification are enclosed. Copies of the references cited in the International Search Report are not enclosed because the Notification of Acceptance of Application Under 35 U.S.C. § 371 and 37 C.F.R. § 1.494 or

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on August 29, 2001.

Barbara E. Johnson, Registration No. 31,198
(Name of Registered Representative)

Signature

8/29/2001
Date


1.495 indicates that the International Search Report and the references cited therein were received by the USPTO.

Pursuant to 37 C.F.R. § 1.97(b)(2), no fee is believed to be due for the submission of this Information Disclosure Statement, as it is being submitted within three months of the date of entry of the national stage in an international application. Nevertheless, the Commissioner for Patents is hereby authorized to charge any fees which may be required to Deposit Account No. 23-0650. One original and two copies of this Information Disclosure Statement are enclosed.

Respectfully Submitted,

WEBB ZIESENHEIM LOGSDON
ORKIN & HANSON, P.C.

By



Barbara E. Johnson
Registration No. 31,198
Attorney for Applicants
700 Koppers Building
436 Seventh Avenue
Pittsburgh, PA 15219-1818
Telephone: (412) 471-8815
Facsimile: (412) 471-4094

Sheet 1 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
702-010411

SERIAL NO.
09/806,178

APPLICANT
Nobuo NAGAI et al.

FILING DATE
June 18, 2001

GROUP
ART UNIT Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL	9 8 1 2 3 2 9	03/1998	WIPO				
	AM	0 6 3 1 7 8 6	04/1995	European Patent Office				
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ	Butte, A. et al., "Alpha2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism," <i>Circulation</i> 95(7): 1886-1891(1997)
AR	Reed, G., "Functional characterization of monoclonal antibody inhibitors of alpha2-antiplasmin that accelerate fibrinolysis in different animal plasmas," <i>Hybridoma</i> 16(3): 281-286 (1997)
AS	Nagai, N., et al. "Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice," <i>Circulation</i> 99(18): 2440-2444 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
702-010411

SERIAL NO.
09/806,178

APPLICANT
Nobuo NAGAI et al.

FILING DATE
June 18, 2001

GROUP
ART UNIT Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AT	Collen, D. "Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent," <i>Nature Medicine</i> 4(3): 279-284 (1998)
	AU	Coyle, J.T. et al. "Oxidative stress, glutamate and neurodegenerative disorders," <i>Science</i> 262: 689-695 (1993)
	AV	Coyle, J.T. et al. "In situ injection of kainic acid: a new method for selectively lesioning neuronal cell bodies while sparing axons of passage," <i>J Comp Neurol</i> 180: 301-323 (1978)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 3 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 702-010411	SERIAL NO. 09/806,178
	APPLICANT Nobuo NAGAI et al.	
	FILING DATE June 18, 2001	GROUP ART UNIT Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AW	Tsirka, S.E. et al. "Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator," <i>Nature</i> 377: 340-344 (1995)
	AX	Tsirka, S.E. et al. "An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus," <i>J Neurosci</i> 17(2): 543-552 (1997)
	AY	Tsirka, S.E. et al. "Neuronal cell death and t-PA," <i>Nature</i> 384: 123-124 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 4 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 702-010411	SERIAL NO. 09/806,178
	APPLICANT Nobuo NAGAI et al.	
	FILING DATE June 18, 2001	GROUP ART UNIT Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AZ	Chen, Z.L. et al. "Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin," <i>Cell</i> 91: 917-925 (1997)
	BA	Wang, Y.F. et al. "Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPa-deficient mice," <i>Nature Medicine</i> 4(2): 228-231 (1998)
	BB	Nagai, N. et al. "Comparative effects of tissue-type plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models," <i>Circulation</i> 100: 2541-2546 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 5 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 702-010411	SERIAL NO. 09/806,178
	APPLICANT Nobuo NAGAI et al.	
	FILING DATE June 18, 2001	GROUP ART UNIT Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group "Tissue plasminogen activator for acute ischemic stroke," <i>N Engl J Med</i> 333(24): 1581-1587 (1995)
BD	Hacke, W. et al. for the ECASS Study Group "Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS)," <i>J Am Med Ass</i> 274(13): 1017-1025 (1995)
BE	Colten, D. et al. "Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma," <i>Blood</i> 53(2): 313-324 (1979)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 6 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 702-010411	SERIAL NO. 09/806,178
	APPLICANT Nobuo NAGAI et al.	
	FILING DATE June 18, 2001	GROUP ART UNIT Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BF	Carmeliet, P. et al. "Physiological consequences of loss of plasminogen activator gene function in mice," <i>Nature</i> 368: 419-424 (1994)
BG	Carmeliet, P. et al. "Plasminogen activator inhibitor-1 gene-deficient mice: I. Generalization by homologous recombination and characterization," <i>J Clin Invest</i> 92: 2746-2755 (1993)
BH	Carmeliet, P. et al. "Plasminogen activator inhibitor-1 gene deficient mice: II. Effects on hemostasis, thrombosis, and thrombolysis," <i>J Clin Invest</i> 92:2756-2760 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 7 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 702-010411	SERIAL NO. 09/806,178
	APPLICANT Nobuo NAGAI et al.	
	FILING DATE June 18, 2001	GROUP ART UNIT Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	BI	Floplis, V.A. et al. "Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice," <i>Circulation</i> 92(9): 2585-2593 (1995)
	BJ	Lijnen, H.R. et al. "Alpha2-antiplasmin gene-deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding," <i>Blood</i> 93(7): 2274-2281 (1999)
	BK	Dewerchin, M. et al. "Generation and characterization of urokinase receptor-deficient mice," <i>J Clin Invest</i> 97(3): 870-878 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 8 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 702-010411	SERIAL NO. 09/806,178
	APPLICANT Nobuo NAGAI et al.	
	FILING DATE June 18, 2001	GROUP ART UNIT Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	BL	Lijnen, H.R. et al. "Amino-acid sequence of human Alpha2-antiplasmin," <i>Eur J Biochem</i> 166: 565-574 (1987)
	BM	McGrory, W.J. et al. "A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5," <i>Virology</i> 163: 614-617 (1988)
	BN	Gomez-Foix, A.M. et al. "Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism," <i>J Biol Chem</i> 267(35): 25129-25134 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 9 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 702-010411	SERIAL NO. 09/806,178
	APPLICANT Nobuo NAGAI et al.	
	FILING DATE June 18, 2001	GROUP ART UNIT Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	BO	Graham, F.L. et al. "Characteristics of a human cell line transformed by DNA from human adenovirus type 5," <i>J Gen Virol</i> 36: 59-72 (1977)
	BP	Gerard, R.D., Meidel, R.S. "Adenovirus vectors. In: Hames, B.D., Glover, D. (eds.) <i>DNA Cloning 4 - A practical approach: mammalian systems</i> ," Oxford, UK, pp. 285-306 (1995)
	BQ	Alcorn, J.L. et al. "Genomic elements involved in transcriptional regulation of the rabbit surfactant protein-A gene," <i>Mol Endocrinol</i> 7(8): 1072-1085 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 10 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 702-010411	SERIAL NO. 09/806,178
	APPLICANT Nobuo NAGAI et al.	
	FILING DATE June 18, 2001	GROUP ART UNIT Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BR	Kopfler, W.P. et al. "Adenovirus-mediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol," <i>Circulation</i> 90(3): 1319-1327 (1994)
BS	Carmeliet, P. et al. "Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice," <i>Blood</i> 90(4): 1527-1534 (1997)
BT	Carmeliet, P. et al. "Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation," <i>Circulation</i> 96(9): 3180-3191 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 11 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 702-010411	SERIAL NO. 09/806,178
	APPLICANT Nobuo NAGAI et al.	
	FILING DATE June 18, 2001	GROUP ART UNIT Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BU	Deutsch, D.G. et al. "Plasminogen purification from human plasma by affinity chromatography," <i>Science</i> 170: 1095-1096 (1970)
BV	Edy, J. et al. "Inhibition of plasmin by normal and antiplasmin-depleted human plasma," <i>Thromb. Res.</i> 8: 513-518 (1976)
BW	Welsh, F.A. et al. "Effect of lactacidosis on pyridine nucleotide stability during ischemia in mouse brain," <i>J Neurochem</i> 49(3): 846-851 (1987)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 12 of 12

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 702-010411	SERIAL NO. 09/806,178
	APPLICANT Nobuo NAGAI et al.	
	FILING DATE June 18, 2001	GROUP ART UNIT Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BX	Bederson, J.B. et al. "Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination," <i>Stroke</i> 17(3): 472-476 (1986)
BY	Bederson, J.B. et al. "Evaluation of 2, 3, 5-triphenyltetrazolium chloride as a stain for detection and quantification of Experimental cerebral infarction in rats," <i>Stroke</i> 17(6): 1304-1308 (1986)
BZ	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.